{"id":863,"date":"2022-04-11T12:30:35","date_gmt":"2022-04-11T12:30:35","guid":{"rendered":"https:\/\/avaeh.org\/web_nueva_2021\/?p=863"},"modified":"2022-04-11T12:30:35","modified_gmt":"2022-04-11T12:30:35","slug":"fase-2-de-terapia-oral-ptc518-de-ptc-therapeutics-para-enfermedad-de-huntington","status":"publish","type":"post","link":"https:\/\/avaeh.org\/web_nueva_2021\/2022\/04\/11\/fase-2-de-terapia-oral-ptc518-de-ptc-therapeutics-para-enfermedad-de-huntington\/","title":{"rendered":"Fase 2 de terapia oral PTC518 de PTC Therapeutics para Enfermedad de Huntington"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a rel=\"noreferrer noopener\" href=\"https:\/\/huntingtonsdiseasenews.com\/2022\/04\/05\/phase-2-trial-oral-ptc518-huntingtons-launched-us-ptc-therapeutics\/\" target=\"_blank\">ART\u00cdCULO COMPLETO<\/a> &#8211; en Huntingtons Disease News<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a rel=\"noreferrer noopener\" href=\"https:\/\/hdsa.org\/blog\/ptc-therapeutics-initiates-recruitment-of-pivot-hd-study\/\" target=\"_blank\">ART\u00cdCULO COMPLETO<\/a> &#8211; en Huntington&#8217;s Disease Society of America<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00abUn ensayo de Fase 2 que eval\u00faa\u00a0<a href=\"https:\/\/www.ptcbio.com\/our-pipeline\/portfolio-pipeline\/\">PTC518<\/a>\u00a0, un tratamiento de investigaci\u00f3n para\u00a0<a href=\"https:\/\/huntingtonsdiseasenews.com\/what-is-huntingtons-disease\">la enfermedad de Huntington<\/a>\u00a0, ha comenzado en los EE. UU., anunci\u00f3\u00a0<a href=\"https:\/\/www.ptcbio.com\/\">PTC Therapeutics<\/a>\u00a0.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El ensayo, denominado PIVOT-HD, se realizar\u00e1 en centros cl\u00ednicos de todo el mundo y se divide en dos partes.&nbsp;Primero, los participantes ser\u00e1n asignados aleatoriamente a un placebo o PTC518 y se les har\u00e1 un seguimiento durante 12 semanas (aproximadamente tres meses).&nbsp;Esta primera parte evaluar\u00e1 la farmacolog\u00eda y el efecto farmacodin\u00e1mico de PTC518, o las&nbsp;interacciones entre el cuerpo y un compuesto determinado.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En la segunda parte, se seguir\u00e1 a los participantes durante nueve meses y los investigadores evaluar\u00e1n el impacto de PTC518 en los biomarcadores de enfermedades.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00abEstamos emocionados de avanzar en nuestro programa de la enfermedad de Huntington\u00bb, dijo en un\u00a0<a href=\"https:\/\/www.prnewswire.com\/news-releases\/ptc-therapeutics-announces-initiation-of-pivot-hd-phase-2-clinical-trial-to-evaluate-ptc518-in-patients-with-huntingtons-disease-301514222.html\">comunicado de prensa<\/a>\u00a0Stuart W. Peltz, PhD, director ejecutivo de PTC Therapeutics, que est\u00e1 desarrollando la terapia .\u00bb<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ART\u00cdCULO COMPLETO &#8211; en Huntingtons Disease News ART\u00cdCULO COMPLETO &#8211; en Huntington&#8217;s Disease Society of America \u00abUn ensayo de Fase 2 que eval\u00faa\u00a0PTC518\u00a0, un tratamiento de investigaci\u00f3n para\u00a0la enfermedad de Huntington\u00a0, ha comenzado en los EE. UU., anunci\u00f3\u00a0PTC Therapeutics\u00a0. El ensayo, denominado PIVOT-HD, se realizar\u00e1 en centros cl\u00ednicos de todo [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-863","post","type-post","status-publish","format-standard","hentry","category-sin-categoria"],"_links":{"self":[{"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/posts\/863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/comments?post=863"}],"version-history":[{"count":1,"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/posts\/863\/revisions"}],"predecessor-version":[{"id":864,"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/posts\/863\/revisions\/864"}],"wp:attachment":[{"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/media?parent=863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/categories?post=863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/avaeh.org\/web_nueva_2021\/wp-json\/wp\/v2\/tags?post=863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}